Skip to content

Early diagnosis and treatment of male children with Kallmann syndrome

Early diagnosis and treatment of male children with Kallmann syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055213
Enrollment
Unknown
Registered
2022-01-03
Start date
2022-01-03
Completion date
Unknown
Last updated
2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kallmann syndrome (KS)

Interventions

KS group:None
Constitutional adolescent developmental delay children group:None

Sponsors

Wuhan Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
4 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clinical and genetic diagnosis of KS. 2. There are clinical manifestations of hypogonadism: the penis and testis are significantly smaller than children of the same age or cryptorchidism, the vulva is immature, and there is no pubic hair development. 3. Anosmia or hyposmia, or MRI of the olfactory bulb suggests unilateral or bilateral absence or hypoplasia of the olfactory bulb and olfactory tract. 4. Low levels of sex hormones LH, FSH, TT, and prepubertal levels. 5. GnRH stimulation experiments showed that gonadotropins were low. The domestic IHH consensus holds that when men use gonarelin or triptorelin for GnRHa excitation test, the cut-off value of the 60-minute LH level is 8IU/L and 4u/1, respectively. 6. KS-related pathogenic genes were detected. 7. Exclude other: (1) Brain magnetic resonance imaging showed no abnormality in the morphology and structure of the hypothalamus and pituitary gland; (2) Hypothalamus-pituitary-thyroid gland; (3) There is no obvious abnormality in the function of the adrenal gland/growth hormone axis; (4) There is no obvious abnormality in prolactin; blood and urine routine, liver and kidney function, electrolytes, myocardial enzymes and other indicators are not abnormal; (5) The chromosomal karyotype is normal, and chromosomal abnormalities are excluded.

Exclusion criteria

Exclusion criteria: 1. History of chemotherapy, radiotherapy, and tumor; 2. Those with other major systemic diseases.

Design outcomes

Primary

MeasureTime frame
Luteinizing hormone;Follicle stimulating hormone;

Countries

China

Contacts

Public ContactLi Ruizhen

Wuhan Children's Hospital

dr_lrz@163.com+86 15327413492

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026